Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 927

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma

Open access
Zhang, Yuan, Chen, Lei, Hu, Guo-Qing, Zhang, Ning, Zhu, Xiao-Dong, Yang, Kun-Yu, Jin, Feng, Shi, Mei, Chen, Yu-Pei, Hu, Wei-Han, Cheng, Zhi-Bin, Wang, Si-Yang, Tian, Ye, Wang, Xi-Cheng, Sun, Yan, Li, Jin-Gao, Li, Wen-Fei, Li, Yu-Hong, Tang, Ling-Long, Mao, Yan-Ping, Zhou, Guan-Qun, Sun, Rui, Liu, Xu, Guo, Rui, Long, Guo-Xian, Liang, Shao-Qiang, Li, Ling, Huang, Jing, Long, Jin-Hua, Zang, Jian, Liu, Qiao-Dan, Zou, Li, Su, Qiong-Fei, Zheng, Bao-Min, Xiao, Yun, Guo, Ying, Han, Fei, Mo, Hao-Yuan, Lv, Jia-Wei, Du, Xiao-Jing, Xu, Cheng, Liu, Na, Li, Ying-Qin, Chua, Melvin L. K., Xie, Fang-Yun, Sun, Ying, Ma, Jun·2019·New England Journal of Medicine

Abstract

BACKGROUND: Platinum-based concurrent chemoradiotherapy is the standard of care for patients with locoregionally advanced nasopharyngeal carcinoma. Additional gemcitabine and cisplatin induction chemotherapy has shown promising efficacy in phase 2 trials. METHODS: In a parallel-group, multicenter, randomized, controlled, phase 3 trial, we compared gemcitabine and cisplatin as induction chemotherapy plus concurrent chemoradiotherapy with concurrent chemoradiotherapy alone. Patients with locoregionally advanced nasopharyngeal carcinoma were randomly assigned in a 1:1 ratio to receive gemcitabine (at a dose of 1 g per square meter of body-surface area on days 1 and 8) plus cisplatin (80 mg per square meter on day 1), administered every 3 weeks for three cycles, plus chemoradiotherapy (concurrent cisplatin at a dose of 100 mg per square meter every 3 weeks for three cycles plus intensity-modulated radiotherapy) or chemoradiotherapy alone. The primary end point was recurrence-free survival (i.e., freedom from disease recurrence [distant metastasis or locoregional recurrence] or death from any cause) in the intention-to-treat population. Secondary end points included overall survival, treatment adherence, and safety. RESULTS: A total of 480 patients were included in the trial (242 patients in the induction chemotherapy group and 238 in the standard-therapy group). At a median follow-up of 42.7 months, the 3-year recurrence-free survival was 85.3% in the induction chemotherapy group and 76.5% in the standard-therapy group (stratified hazard ratio for recurrence or death, 0.51; 95% confidence interval [CI], 0.34 to 0.77; P = 0.001). Overall survival at 3 years was 94.6% and 90.3%, respectively (stratified hazard ratio for death, 0.43; 95% CI, 0.24 to 0.77). A total of 96.7% of the patients completed three cycles of induction chemotherapy. The incidence of acute adverse events of grade 3 or 4 was 75.7% in the induction chemotherapy group and 55.7% in the standard-therapy group, with a higher incidence of neutropenia, thrombocytopenia, anemia, nausea, and vomiting in the induction chemotherapy group. The incidence of grade 3 or 4 late toxic effects was 9.2% in the induction chemotherapy group and 11.4% in the standard-therapy group. CONCLUSIONS: Induction chemotherapy added to chemoradiotherapy significantly improved recurrence-free survival and overall survival, as compared with chemoradiotherapy alone, among patients with locoregionally advanced nasopharyngeal carcinoma. (Funded by the Innovation Team Development Plan of the Ministry of Education and others; ClinicalTrials.gov number, NCT01872962.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1905287

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 927

Metadata

Authors
Zhang, Y., Chen, L., Hu, G.-Q., Zhang, N., Zhu, X.-D., Yang, K.-Y., Jin, F., Shi, M., Chen, Y.-P., Hu, W.-H., Cheng, Z.-B., Wang, S.-Y., Tian, Y., Wang, X.-C., Sun, Y., Li, J.-G., Li, W.-F., Li, Y.-H., Tang, L.-L., Mao, Y.-P., Zhou, G.-Q., Sun, R., Liu, X., Guo, R., Long, G.-X., Liang, S.-Q., Li, L., Huang, J., Long, J.-H., Zang, J., Liu, Q.-D., Zou, L., Su, Q.-F., Zheng, B.-M., Xiao, Y., Guo, Y., Han, F., Mo, H.-Y., Lv, J.-W., Du, X.-J., Xu, C., Liu, N., Li, Y.-Q., Chua, M. L. K., Xie, F.-Y., Sun, Y., & Ma, J.
Venue
New England Journal of Medicine
Published
2019-09-19
Volume
381
Issue
12
Pages
1124-1135
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2947165726
Cited by
927
References
23
FWCI
84.50
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. https://app.cochat.ai/papers/10.1056/nejmoa1905287
The paper
Zhang, Y., Chen, L., Hu, G.-Q., Zhang, N., Zhu, X.-D., Yang, K.-Y., Jin, F., Shi, M., Chen, Y.-P., Hu, W.-H., Cheng, Z.-B., Wang, S.-Y., Tian, Y., Wang, X.-C., Sun, Y., Li, J.-G., Li, W.-F., Li, Y.-H., Tang, L.-L., . . . Ma, J. (2019). Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1905287

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.